Titan Pharmaceuticals Announces Probuphine Presentation at American Society of Addiction Medicine Conference
Dr. Walter Ling Invited to Discuss Probuphine at ASAM's State of the Art Course in Addiction Medicine
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 10/20/11 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that Walter Ling, M.D. will make a presentation about Probuphine™ and prescription drug abuse at the American Society of Addiction Medicine (ASAM) State of the Art Course in Addiction Medicine on October 27, 2011 at 4 p.m. ET in Washington DC. Dr. Ling is a Professor of Psychiatry, Director, Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA and a lead investigator in Titan's recently completed, successful Phase 3 confirmatory study of Probuphine in patients with opioid dependence.
Dr. Ling's session, "Probuphine and Other Agents to Treat Prescription Drug Abuse," is scheduled to be part of the meeting's Session 2, "Use and Abuse of Prescription Opioids: Current Evidence." It will be followed by a faculty-audience discussion and question and answer session. Katherine Beebe, Ph.D., Executive Vice President and Chief Development Officer of Titan, will also be in attendance to participate in the question and answer session.
About ASAM's State of the Art Course in Addiction Medicine
ASAM's 2011 Course on the State of the Art in Addiction Medicine will meet October 27-29, 2011 at the Washington Hilton Hotel in Washington, DC. The course focuses on cutting-edge research and the potential of such research to enrich the clinical practice of addiction medicine. It is offered only once every two years so that each event presents true advances in the field. Unlike typical conferences that feature multiple simultaneous workshops, the ASAM State of the Art Course offers a three-day curriculum that showcases a series of carefully selected lectures and audience interactions in a single plenary session, supported by an extensive syllabus in print and electronic form. The State of the Art Course is offered in partnership with the Center for Substance Abuse Prevention and the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration, and with the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse of the National Institutes of Health.
Probuphine is an innovative, subcutaneous implant formulation that delivers a steady, round-the-clock dose of the marketed drug buprenorphine over six months following a single treatment and is being developed by Titan for the treatment of opioid dependence. The safety and effectiveness of treatment with Probuphine has been demonstrated in several Phase 3 studies conducted to date, including a 163-patient placebo-controlled study which demonstrated clinically meaningful and statistically significant treatment with Probuphine over a 24-week period and was published in the Journal of the American Medical Association (JAMA) and a confirmatory study of 287 patients that showed statistically significant efficacy versus placebo and non-inferiority with a currently marketed sublingual formulation of buprenorphine. Titan has announced that the U.S. Food and Drug Administration (FDA) has confirmed an October 25, 2011 Pre-New Drug Application (Pre-NDA) meeting to review all elements of the Probuphine development program. At this meeting the company will seek FDA input and guidance on the proposed content of a New Drug Application (NDA).
About Titan Pharmaceuticals
For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at www.titanpharm.com.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
CONTACT: Titan Pharmaceuticals, Inc. Sunil Bhonsle 650-244-4990 President Pure Communications Dan Budwick 973-271-6085 email@example.com
Source: Titan Pharmaceuticals, Inc.
Released October 20, 2011